THE CHALLENGE OF TREATING EPILEPSY IN PREGNANCY: MATERNAL AND OFFSPRING PERSPECTIVES by Babikir, Haydar E.
EDITORIAL  
 
Gezira Journal Of Health Sciences 2001 vol.6(2)  
 
Gezira Journal of Health Sciences 2001 vol.6 (2) 
 
THE CHALLENGE OF TREATING EPILEPSY IN PREGNANCY: MATERNAL AND 
OFFSPRING PERSPECTIVES 
Haydar E. Babikir M.D. 
University of Geizera, Wad Medani, Sudan. 
SUMMARY 
Epilepsy is a common medical and social disorder and usually defined as a tendency to recurrent 
seizures. Freedom from seizures is the ultimate goal in treatment of patients with epilepsy. At the same 
time, the side effects of antiepileptic drugs (AEDs) should not outweigh the benefits of treatment. This is 
particularly important in epileptic women who wish to become pregnant. Those women have a higher risk 
for pregnancy-related complications. For babies whose mothers take AEDs, the risk of birth defects is 4 to 
8 percent, compared with 2 to 3 percent for controls. The risk seems to be highest when multiple AEDs are 
taken, but without medication, uncontrolled seizures may deprive the baby of oxygen. Seizures can also 
increase the risk of miscarriage or stillbirth. By working with her physicians, a woman with epilepsy can 
become pregnant and have a happy outcome. 
In the Sudan we lack national epidemiological studies using standardized definitions and case 
ascertainment methods on epilepsy as general and in pregnancy, but according to the WHO the number 
of people with epilepsy is high in most regions of the world. The mean number per 1000 population is 
8.93 (SD 8.14, median 7.59). This knowledge is essential for the identification of needs and the planning 
of appropriate services. This a thorough review of more than 40 articles published over the last 10 years. 
However, it is not a complete reference for designing a protocol for the management of epilepsy in 
pregnant women. It aims at discussing current management of epilepsy and pregnancy, including the fetal 
outcome and teratogenicity of AEDs. It is part of a series mandated by the Gezira Epilepsy Care Program 
(GECP), to obtain baseline data for a community-adapted epilepsy education and awareness program.  
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Introduction 
The number of pregnant women with epilepsy has risen as seizures have been well controlled with 
modern pharmacotherapy. Up to 5% of pregnancies occur in epileptic women. The combination might seem 
risky. Some women who have epilepsy have menstrual irregularities and other gynecological problems that 
may make it harder to conceive. 
Antiepileptic drug treatment, hormonal changes, and vitamin deficiency can affect seizure patterns, 
even for women who have had excellent seizure control in the past. These and genetic factors may increase 
the risk for birth defects in infants born to epileptic mothers.1 Although this risk is not significant enough 
to avoid pregnancy, epileptologists advise attentive care for epileptic mothers. Regular and early prenatal 
care makes more than 90 percent of pregnant women who have epilepsy deliver healthy babies.1 
Women who have epilepsy predisposed to a higher risk of pregnancy-related complications, 
including; vaginal bleeding during and after pregnancy, abruption placenta and preeclampsia. Difficulties 
during labor and delivery include premature labor, failure to progress, and an increased rate of cesarean 
sections.2  
Every woman reacts to pregnancy differently with respect to seizures frequency. Most epileptic 
pregnant women have no changes in seizures frequency, whereas, for a few, seizures become less frequent. 
Pregnant mothers with poorly controlled epilepsy have increased number of seizures. For most women, 
however, it's best to continue treatment during pregnancy to minimize the risks for her and her baby.3 
Women with epilepsy are potentially at risk of fetal malformations, which is further increased with the use 
of antiepileptic drugs (AEDs).4 
Reducing AEDs dosage or discontinuing medication is unsafe because uncontrolled seizures can 
reduce uterine oxygen or blood supply, which puts both the woman and the developing fetus at risk.5 Also, 
changes in treatment can immediately alter the concentration of medication in the body, which may lead to 
sudden changes, especially during pregnancy that may lead to status epilepticus, where the risk to a mother 
and a developing fetus is high. Therefore, any decision to discontinue AED therapy during pregnancy, 
particularly if a patient has not experienced seizures for several months, should be made at the discretion 
of the treating physician only.6   
EPILEPSY AND PREGNANCY 
Incidence of Epilepsy and Pregnancy 
Up to 5% of pregnancies occur in epileptic women and approximately 20% of women with epilepsy 
experience an increase of episodes during pregnancy. Pregnancy affects each woman who has epilepsy 
differently. Some experience seizures only while giving birth. Whereas, some women experience fewer 
seizures than normal while pregnant.7  
Effect of Pregnancy on Seizures 
During pregnancy, one quarter to one third of women with epilepsy have an increase in seizure 
frequency despite continued use of AEDs. Certain physiological changes that occur during pregnancy may 
lead to increased frequency, and difficulty control of seizures in some women with epilepsy.8 Uncontrolled 
seizures, particularly generalized tonic-clonic episodes, are hazardous during pregnancy and discontinuing 
AEDs may pose a greater risk for both mother and fetus than the possible adverse effects of the medication. 
A theoretical risk of abruptio placentae exists, possibly leading to fetal hypoxia or death. Furthermore, the 
risk of maternal aspiration can lead to maternal hypoxia, which can also lead to fetal hypoxia. Evidence 
indicates seizure frequency increases during 17-33% of pregnancies.9 This is usually in the last trimester or 
peripartum. Several possible etiologies have been proposed for this occurrence. These changes include; 
increased hormone production, altered eating habits, increased stress, altered metabolism of AEDs due to 
increased blood volume leads to increased volume of distribution. Severe nausea and vomiting during early 
pregnancy may upset the balance as well.  
Generally, sleep deprivation influences seizure frequency for those who suffer from epilepsy. A 
significant increase in seizure occurrence may result during pregnancy when sleep patterns change. Stress 
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and changes in eating and sleeping habits may also contribute to more frequent seizure activity in some 
cases.10  
Renal function increases during pregnancy, with a 50% rise in creatinine clearance, which impacts 
the metabolism of carbamazepine, primidone, and benzodiazepines. The increase in total blood volume and 
a concomitant rise in the distribution volume also lead to decreased levels of circulating AEDs. In contrast, 
the decrease in albumin and circulating plasma proteins likely increases the free component of the AEDs 
in serum.11 
Many women are hormonally sensitive. Estrogen and progesterone increase naturally and steadily 
during normal pregnancy. Increased levels of circulating estrogen during pregnancy increase the function 
of the P-450 enzymes, which leads to more rapid hepatic metabolism of the AEDs.12 Estrogen and 
progesterone hormones act in opposite ways in terms of electrical excitability of the brain. In experimental 
models estrogen increases the electrical activity of the brain by lowering the seizures threshold, whereas, 
progesterone elevates seizure threshold and may have an antiepileptic effect. Fluctuations in the levels of 
these hormones during pregnancy can make it more difficult for epileptic women to predict and control 
seizures. Adjusting the ratio of estrogen and progesterone isn't a substitute for AEDs, but hormone 
supplementation on top of regular seizure medicines really might improve things.13 
Pregnant women may have decreased compliance with taking AEDs because of concerns regarding 
the effects on their fetuses. It is therefore very important to monitor levels closely during pregnancy and to 
adhere to prescribed treatment.14 This needs frequent dosage adjustments to maintain seizure control. Serum 
levels of AEDs should be obtained at the end of each trimester. Plasma levels of unbound AEDs should be 
monitored closely throughout pregnancy and for at least 8 weeks following delivery, as it is common for 
levels to rise in the postpartum period. Free levels, for highly protein bound drugs such as valporic acid or 
phenytoin give a better indication of whether dose adjustments are needed.15 
Rarely, some patients experience their first seizures during pregnancy. This can be a result of true 
gestational epilepsy, a rare syndrome of seizures occurring only during pregnancy. Patients with this 
syndrome have a variable presentation with single or multiple seizures in one or more of their pregnancies. 
It can also be a manifestation of epilepsy that may extend beyond the pregnancy.16The differential diagnosis 
should include eclampsia and preeclampsia and any possible etiology considered in the non-pregnant 
patient, including stroke, electrolyte abnormalities, tumor, trauma, drugs withdrawal, and epilepsy.17  
Eclampsia is defined as one or more tonic-clonic seizures in a patient with preeclampsia which 
includes recently elevated blood pressure, proteinuria and elevated liver enzymes. Associated 
encephalopathy is related to vasoconstriction, cerebral oedema, micro-hemorrhages and disseminated 
intravascular coagulation. Treatment consists of control of hypertension, management of cerebral edema 
and control of seizures. Conventional AEDs, such as benzodiazepines or phenytoin, have been used, but 
magnesium sulphate had been found to be more effective and must be used as an initial therapy in 
hypertensive patients during labor.  
Preparing for pregnancy 
More than 90 % of women with epilepsy will have normal, healthy infants. However, they are at 
greater risk for complications of pregnancy, labor and adverse pregnancy outcomes than women without 
epilepsy. Despite the great worries associated with pregnancy in epileptic women or who are trying to 
become pregnant, it had been confirmed that most women with epilepsy can and do have normal 
pregnancies.17 Some well-documented risks are associated with taking AEDs while pregnant, but the 
answer usually is not to stop AEDs as maternal seizures have their own hazards such as induction of 
premature labor and miscarriage following a generalized tonic clonic seizure.18  
 
Unplanned Pregnancies 
Oral contraceptive failure increased four to five times in women with epilepsy taking certain anti-
epileptic drugs (AEDs). This hormonal birth control failure is due to induction of estrogen metabolism and 
to a lesser extent progesterone metabolism by many AEDS, such as carbamazepine, oxcarbazepine, 
phenytoin, barbiturates and topiramate.19 
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Fertility and hormonal influences 
Women with epilepsy have fewer children than the general population, with a fertility rate 25 to 33 
percent lower than average. 20 Research has indicated that women with epilepsy have a higher incidence of 
menstrual irregularities, polycystic ovarian disease and reproductive endocrine disorders due to side effects 
of AEDs (e.g., valporic acid) or induction of sex hormone metabolism by hepatic enzyme-inducing agents.20 
A population-based study conducted in Iceland have contradicting results showing that there was no 
reduction in fertility, except when mental retardation or congenital neurologic impairment was present. 
They suggested that fertility may not be reduced by epilepsy or its treatment.21 
Anti-EPILEPTIC DRUGS AND BREASTFEEDING 
Breast feeding is beneficial; its immunological and nutritional value to the newborn infant is greater 
than that of formula milk. Many common AEDs cross the placenta, and may show up in breast milk at low 
levels, there is no evidence of harm to the newborns with the exception of valproate and, to a lesser extent, 
phenobarbital and phenytoin. If those mothers can avoid valproate, then there will be minimal adverse 
outcomes in their children.22 AEDs, primidone, and levetiracetam were detected in breast milk at various 
clinically important levels. However, it has to be stressed that women should not stop taking any drug 
without consulting their physicians who have to weigh the potential risk of birth defects against the potential 
risk of uncontrolled seizures.23 
FETAL CONGENITAL ABNORMALITIES AND ADVERSE OUTCOMES 
Drugs can have harmful effects on the fetus at any time during pregnancy. It is important to bear 
this in mind when prescribing for a woman of childbearing age.  During the first trimester AEDs may 
produce congenital malformations and the period of greatest risk is from the third to the eleventh week of 
pregnancy. During the second and third trimester AEDs may affect the growth and functional development 
of the fetus or have toxic effects on fetal tissues, and drugs given shortly before term or during labor may 
have adverse effects on labor or on the neonate after delivery.24 
Major malformations are defined as defects of medical, surgical or cosmetic importance. This type 
of anomaly, which will seriously affect a child’s life, occurs in 2 to 3 percent of all live born children. The 
risk of malformation is about twice that for the general population. Birth defects occur in 4% to 6% of 
infants born to women with epilepsy.25 For women with epilepsy on one AED, the incidence is estimated 
to be 4 to 8 percent and possibly greater for women on polytherapy. Types of major malformations 
occurring most often in children of women with epilepsy are orofacial clefts, cardiac abnormalities and 
neural tube defects.26 Ultrasound between 16 and 18 weeks gestation to check for abnormalities with an 
accuracy rate of over 95% is recommended during the antenatal care visits. Minor Anomalies such as 
hypertelorism, epicanthal folds, shallow philtrum, distal digital hypoplasia, and simian creases are often 
present as a familial trait and do not cause any serious problems and are primarily of cosmetic concern. The 
incidence of minor physical defects in infants born to women with epilepsy is approximately 15 percent.27 
A greater incidence of mental retardation and/or microcephaly has been reported, but these studies 
have been inconsistent and have not always been controlled for other possible contributing factors such as 
inherent genetics, and the effects of maternal seizures or AEDs in utero.28 However, developmental delays 
may be significant in terms of risk to infants of women with epilepsy. Factors other than the maternal 
epilepsy that are thought to be important are IQ scores in the mother and AED polypharmacy particularly 
exposure to phenobarbital in utero.29 The development of language skills in particular tends to be slower. 
This is reported in 2% to 6% of births and sometimes is not permanently impaired; however, catch up 
varies.30 A differential effect of individual AEDs has been identified in retrospective and prospective 
studies of young and older children who were exposed to AEDs in utero. Phenobarbital exposure resulted 
in a 7-point reduction in verbal IQ in adult men who had been exposed to phenobarbital during gestation, 
compared with controls whose mothers did not take AEDs during pregnancy.31 
Long-term studies on neurodevelopment show higher rates of abnormal EEG findings, higher rates 
of developmentally delayed children, and lower intelligence quotient (IQ) scores.32 
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These babies also have a slightly higher risk of developing seizures as they get older.33 
Developmental delays are possible as well.34  
There is no increased risk of early fetal death following spontaneous abortion within the first 20 weeks 
post-conception in women with epilepsy. Whereas, late fetal loss shows as much as twofold increased in 
incidence in women with epilepsy.35  
Distinctive malformations and syndromes have been ascribed to phenytoin, phenobarbital, 
primidone, valproate, carbamazepine, and trimethadione. Specific increases in congenital abnormalities 
observed in infants born to mothers with epilepsy include a 4-fold increase in cleft lip and palate and a 3- 
to 4-fold increase in cardiac anomalies.36 An increase in the rate of neural tube defects is also observed in 
the offspring of patients with epilepsy who are using valproic acid (1-2%) or carbamazepine (0.5%).37 Folic 
acid supplementation (at a minimum dose of 0.4 mg daily) is especially important prior to conception and 
during pregnancy in women with epilepsy to lower the risk of neural tube defects in the offspring.38 
  Many experts believe that trimethadione is contraindicated in women with epilepsy who might 
become pregnant because it has been associated with a high incidence of fetal loss and congenital 
malformations. 
Most of the literature suggests that first-trimester use of even a single AED is associated with a 2- 
to 5-fold increase in major malformations. Furthermore, multiple studies present evidence indicating an 
increase in fetal malformations with AED polytherapy. All commonly used AEDs have been associated 
with congenital malformations. Lamotrigine metabolism and clearance increases during pregnancy, and 
understanding the effect of pregnancy on lamotrigine concentrations is particularly important as this drug 
is being used increasingly in women who are considering pregnancy.39 Some of the newer AEDs have not 
been used in large enough numbers to have meaningful data (Table 1).40 
MECHANISMS OF TERATOGENICITY 
The mechanisms of teratogenicity of the AEDs have not been fully characterized. All AEDs have a 
similar central mechanism of action, a common pathway that is disrupted during embryogenesis may lead 
to the similarities in the syndromes described, and this may be why an additive effect is observed with 
polytherapy.41 Phenobarbital, primidone, and phenytoin act as folate antagonists, certainly resulting in 
neural tube defects; thus, folate administration prior to conception has been recommended for prophylaxis. 
Recent studies in teratogenesis, particularly fetal hydantoin syndrome, point to a genetic predilection for 
the generation of epoxides. Holmes LB, These anomalies have been observed at an increased rate in 
children whose enzyme activity of epoxide hydrolase is one third less than the reference range. Anomalies 
have also been observed in children with low epoxide hydrolase activity who were exposed to 
carbamazepine.42 Syndromes related to several of the AEDs, and to specific abnormalities observed in 
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Table 1. Teratogenicity and Breast Feeding advices associated with some of the Newer AEDs 
  













Zonisamide   
Present in milk-manufacturers advices avoid 
Present in milk but limited data suggest no harmful effects on 
infants. 
Present in milk-manufacturers advices avoid 
Toxicity in animal studies manufacturers advices  
avoid unless potential benefit outweighs risk 
Present in milk-manufacturers advices avoid 
Present in milk in animal studies-manufacturers advices avoid 
Present in milk-manufacturers advices avoid 
Toxicity in animal studies manufacturers advices  
avoid unless potential benefit outweighs risk 
Present in milk-manufacturers advices avoid 
Present in milk-manufacturers advices avoid. Toxicity and 
tertogenicity reported- manufacturers advices avoid unless 
potential benefit outweighs risk avoid; present in milk-
manufacturers advices avoid breast feeding for 4 weeks after 
administration 
NB. With careful treatment of these patients, more than 90% have an entirely uncomplicated and safe pregnancy. The side effects 
of antiepileptic drugs  should not outweigh the benefits of treatment. 
  
Hereditary epilepsy 
The risk for babies of epileptic mothers to develop epilepsy is two folds of their control. About 2% 
of the children whose mothers have epilepsy will have epilepsy. However, a father with epilepsy does not 
seem to increase the risk.43 
Infant mortality 
Maternal epilepsy increase infant death after birth by two to three times. The rates are high right 
through the first year of life. The reason for the high mortality rate is unclear, but may be ascribed to high 
rate of birth defects.43 In general, the fetus is protected from the physiologic effects of maternal seizures, 
but miscarriages can occur with prolonged seizures or status epilepticus 
Hemorrhagic Disorder of the Newborn 
Bleeding related to certain AEDs was once a major complication in newborn children of mothers 
with epilepsy, but it has been declining. This is a unique hemorrhagic disease of the neonate that occurs in 
the first 24 hours of life. Vitamin K prophylaxis is recommended in the last few weeks of pregnancy, 
starting at approximately week 36. The incidence of hemorrhagic disease in the newborn child has been 
reported to be increased in infants exposed to AEDs during pregnancy—in particular, AEDs that induce 
the Cytochrome P450 enzyme system. Cytochrome P450 enzyme-inducing AEDs, including phenobarbital, 
primidone, phenytoin, carbamazepine and, to a lesser extent, oxcarbazepine and topiramate, induce fetal 
microsomal enzymes, which degrade vitamin K. In addition, these drugs might cause competitive inhibition 
of the addition of calcium-binding γ-carboxyglutamic-acid residues to the precursors of clotting factors II, 
VII, IX and X. Bleeding in AED-exposed infants typically occurs early, and includes intra-abdominal, 
intracranial and intrathoracic locations. Maternal AEDs competitively inhibit vitamin K transport across 
the placenta and the infant has prolonged prothrombin and partial thromboplastin times. vitamin K 
supplementation at a dose of 10 mg/ each day during the last four weeks before delivery is recommended 
as a preventive measure.44  
Low birth weight 
Low birth weight in infants of mothers with epilepsy that is not related to prematurity was reported 
as twice as in the control. 
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Risk of Seizures in the Child 
There is a higher risk for women with epilepsy to have children with the condition than for men 
with epilepsy. Seizure type and age of onset also affect incidence of epilepsy in the child. It is encouraging 
to recognize that even for patients in the highest risk groups, the risk that an offspring will develop epilepsy 
is less than 10 percent.45 
 
MANAGEMENT 
Women with epilepsy should follow the traditional rules for having a healthy pregnancy. 
Preconceptional counseling and coordination of care among all members of the health care team is the key 
to treating women with epilepsy of reproductive age.  
Preconceptual management of women with epilepsy 
Regarding the preconceptual management of women with epilepsy the following measures may be very 
useful;  
 Attempt to decrease pharmacotherapy to monotherapy. Patients are advised to switch to a single 
AED prior to conception and taper to the lowest possible dose, because exposure to multiple 
antiepileptic drugs carries more teratogenic effects. Although this has not been studied in a 
prospective randomized clinical trial, using AED as monotherapy might offer lower fetal/embryonic 
risk. 
 Taper dosages of AEDs to the lowest possible dose. 
 In women who have not had a seizure for 2-5 years, attempt complete withdrawal of 
pharmacotherapy prior to conception. 
 Establish the level of total and free AEDs necessary for achieving good clinical control. Evidence 
indicates that high peak plasma levels of valproic acid may be more teratogenic, this drug should 
be dosed at 3-4 times per day rather than the standard twice-per-day dosing. 
 Consider preconceptual genetic counseling. 
 Supplement the diet with folate at 4 mg/d. Supplemental folate has been shown to decrease neural 
tube defects in patients without epilepsy and decrease other congenital anomalies in women with 
epilepsy. Thus, all women on AEDs, and particularly those using either valproic acid or 
carbamazepine, should be advised to take supplemental folate prior to conception. 
However, patients with epilepsy should be counseled that they are still at a greater risk (ie, 4-6% vs 2-3%) 
for fetal anomalies than the general population. Because of the increased risk, a level II fetal survey should 
be performed at 19-20 weeks' gestation, with careful attention to the face, central nervous system, and heart.  
A fetal echocardiogram should also be considered to diagnose potential cardiac anomalies.  
Management of women with epilepsy during pregnancy 
Maternal serum alpha-fetoprotein (MSAFP) screening test to check for neural tube defects is 
particularly recommended in the setting of a family history of neural tube defects or with the use of valproic 
acid or carbamazepine.46 Although the sensitivity of amniocentesis is higher than either MSAFP screening 
tests or ultrasonography for detecting neural tube defects its routine use is controversial. 
Antiepileptic drugs may increase vitamin K metabolism and inhibition its placental transport, lead 
to increased risk of spontaneous hemorrhage in newborns. Upon delivery, clotting studies can be performed 
on the cord blood, and routine injection of vitamin K at birth effectively counteracts any AEDs associated 
risk of neonatal hemorrhage. However, a study of 204 neonates born to mothers taking AEDs who did not 
received vitamin K supplementation showed no evidence of coagulopathy.43 If the cord blood is deficient 
in clotting factors, fresh frozen plasma may be required to protect the newborn. 
Management of a pregnant patient in status epilepticus  
Status epilepticus carries a high mortality rate for mother and fetus, and generalized seizures 
occurring during labor can result in fetal bradycardia. Rarely, a patient has intractable seizures upon labor 
and delivery. When the seizures last longer than 30 minutes with a continuous seizure or a lack of full 
recovery between seizures, the patient is considered to be in status epilepticus. Preeclampsia and eclampsia 
have to be excluded. 
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The protocol for managing status epilepticus is similar to the management of any seizure, ie, using 
benzodiazepines, phenytoin, and, rarely, phenobarbital. During this situation, the fetus must be monitored. 
Establish an airway and attempt intrauterine resuscitation. If the seizure is not treated easily and the fetal 
testing results is not reassuring for longer than 10 minutes, a neuromuscular blocking agent can be 
administered and emergent cesarean delivery can be performed.18 
 Establish the ABCs, and check vital signs, including oxygenation. 
 Assess the fetal heart rate or fetal status. 
 Rule out eclampsia. 
 Administer a bolus of lorazepam (0.1 mg/kg, i.e., 5-10 mg) at no faster than 2 mg/min. 
 Load phenytoin (20 mg/kg, i.e., 1-2 g) at no faster than 50 mg/min, with cardiac monitoring. 
 If this is not successful, load phenobarbital (20 mg/kg, i.e., 1-2 g) at no faster than 100 mg/min. 
 Check laboratory findings, including electrolytes, AED levels, glucose, and toxicology screen. 
 If fetal testing results are non-reassuring, move to emergent delivery. 
 
Management of women with epilepsy during labor and delivery 
Careful management of pregnant women with epilepsy who are being treated with AEDs is 
important, as seizure frequency can change during pregnancy, and both seizure activity and AED drug 
treatment might have consequences for the developing fetus, including increased rates of stillbirth, 
teratogenesis and cognitive delay. Labor management should be based on routine standards of care and 
should include preparation and close monitoring. However, due to the fact that trauma and hypoxia from a 
seizure can put both the mother and fetus at risk, all care providers, including nurses, anesthesiologists, and 
pediatricians, that the patient has epilepsy, should be informed during labor and delivery that the patient 
has epilepsy and treatment of seizures should be discussed with the team caring for the patient. Manage 
seizures acutely with intravenous benzodiazepines (1-2 mg of diazepam), then load phenytoin (1 g loaded 
over 1 h).18 
Antiepileptic drugs levels should be checked upon admission. If the serum drug level is low, patients 
may be administered extra doses or may be switched over to intravenous benzodiazepines or phenytoin. 
Consider seizure prophylaxis with intravenous benzodiazepines or phenytoin. Manage seizures acutely with 
intravenous benzodiazepines (1-2 mg of diazepam), then load phenytoin (1 g loaded over 1 h). 
Reports of increased risk of spontaneous hemorrhage in newborns suggest that the inhibition of 
vitamin K–dependent clotting factors (ie, II, VII, IX, X) secondary to increased vitamin K metabolism and 
the inhibition of placental transport of vitamin K results from AED use. Historically, most patients on AEDs 
received oral vitamin K supplementation at the end of pregnancy. However, a study of 204 neonates born 
to mothers taking AEDs who did not received vitamin K supplementation showed no evidence of 
coagulopathy.44 Upon delivery, clotting studies can be performed on the cord blood, and vitamin K can be 
administered to the infant. If the cord blood is deficient in clotting factors, fresh frozen plasma may be 
required to protect the newborn. 
 
RECOMMENDATIONS FOR MANAGEMENT OF EPILEPSY IN PREGNANCY 
Issues must be discussed with all epileptic women with childbearing potential. Simplification of regimen 
and optimization of dose before pregnancy is essential if AEDs are really needed.  Key guideline 
recommendations for managing epilepsy during pregnancy include: 
 Consideration must be given to whether AEDs are needed. 
 If possible, women with epilepsy should avoid taking multiple AEDs to reduce the risk of birth 
defects. 
 An epileptic mother should be given the right medication in the right dose. Generally AEDs that are 
effective and well tolerated should not be changed. Initial selection of drugs with the least 
teratogenicity, such ad carbamazepine, clobazam or possibly one of the newer AEDs, is 
recommended in women who wish to become pregnant.47 
 An epileptic mother should be enforced to a have good compliance.  
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 Breastfeeding is a viable option for epileptic mothers on AEDs. Caution and clinical monitoring 
should be exercised if the mother is using phenobarbital, primidone, ethosuximide or lamotrigine. 
AEDs enter the breast milk in inverse proportion to their protein binding. Sedating effects, such as 
the barbiturates, may cause sedation of the newborn.  
 Epileptic pregnant women should have their blood tested and adjusted regularly to keep them 
seizures free. Pregnancy has been shown to lower the levels of AEDs in the blood, which may put 
women at risk of seizures.48  
 They should be close to normal weight levels, and eat a sensible and balanced diet 
 Smoking substantially increases the risk of premature contractions, labor, and delivery in women 
with epilepsy. 
 There is little evidence to support or refute vitamin K supplements during pregnancy to reduce risk 
of perinatal hemorrhage.44 
 Avoid use of valproate as evidence from numerous studies link the drug to major congenital 
abnormalities. These abnormalities include neural tube defects, facial clefts, and hypospadias. 
 Valporic acid and carbamazepine should be avoided if there is a family history of or previous child 
with spina bifida. Phenytoin and phenobarbital should be used with caution because they can impair 
cognitive development in children and the latter may cause withdrawal symptoms after the first 
week postpartum. 
 Use of as few AEDs as possible. There is increased cognitive impairment in children when mothers 
take multiple anticonvulsants during pregnancy. 
 Women who have epilepsy and are considering pregnancy should be consider not doing so until 
they have been seizure-free for at least nine months prior to conception. This will give them an 84-
92% chance of remaining seizure free during pregnancy.  
 Folic acid supplementation is essential as in all pregnant women, it is even more so in women taking 
AEDs. At least 400 micrograms of folic acid a day, as supplementation has been shown to be 
"possibly effective" in preventing major birth defects.  
 Epileptic mothers must be taught precautions when taking care of newborns or young children, such 
as changing and feeding the baby while sitting on a blanket on the floor and never bathing the baby 
alone. 
Conclusion 
Pregnancy in patients with seizure disorders can be complicated by a variety of maternal and fetal 
issues. Patients can experience higher rates of seizures and the fetus is likely to be at increased risk for 
congenital abnormalities and long-term outcomes such as lower IQs and higher rates of developmental 
delay. The teratogenicity effect of AEDs is reduced if treatment is limited to a single drug. 
Epilepsy in a pregnant lady needs management by a team of care providers, including a 
perinatologist and a neurologist, and the mother should be counseled and given antenatal screening.  
The common treatment strategy has been to use the appropriate AED for the woman's seizure 
disorder as monotherapy in the lowest effective dosage throughout pregnancy, the objective being to use 
AEDs in such a way that generalised tonic-clonic seizures are avoided but with minimized risks to the fetus, 
the newborn and the breast-fed infant. Valproic acid should be avoided if possible. 
Issues that need to be addressed in further studies include better differentiation of which AEDs 
result in higher rates of major malformations, defining cognitive effects of in utero AED exposure. Breast 
feeding is generally safe. Larger scale studies are needed to better understand drug transfer in breast milk 
and metabolism in infants for all AEDs , and to establish better guidelines for breastfeeding. 
Acknowledgment: The author gratefully acknowledges the contributions of Dr. Magid Mustafa El Sayed: 
A consultant neurologist, Great Manchester Neuroscience Center, Hope Hospital, Manchester, U.K. in 
reviewing this article. 
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